<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39450171</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The molecular mechanisms of CD8<sup>+</sup> T cell responses to SARS-CoV-2 infection mediated by TCR-pMHC interactions.</ArticleTitle><Pagination><StartPage>1468456</StartPage><MedlinePgn>1468456</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1468456</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1468456</ELocationID><Abstract><AbstractText>Cytotoxic CD8<sup>+</sup> T lymphocytes (CTLs) have been implicated in the severity of COVID-19. The TCR-pMHC ternary complex, formed by the T cell receptor (TCR) and peptide-MHC (major histocompatibility complex), constitutes the molecular basis of CTL responses against SARS-CoV-2. While numerous studies have been conducted on T cell immunity, the molecular mechanisms underlying CTL-mediated immunity against SARS-CoV-2 infection have not been well elaborated. In this review, we described the association between HLA variants and different immune responses to SARS-CoV-2 infection, which may lead to varying COVID-19 outcomes. We also summarized the specific TCR repertoires triggered by certain SARS-CoV-2 CTL epitopes, which might explain the variations in disease outcomes among different patients. Importantly, we have highlighted the primary strategies used by SARS-CoV-2 variants to evade T-cell killing: disrupting peptide-MHC binding, TCR recognition, and antigen processing. This review provides valuable insights into the molecule mechanism of CTL responses during SARS-CoV-2 infection, aiding efforts to control the pandemic and prepare for future challenges.</AbstractText><CopyrightInformation>Copyright © 2024 Deng, Xu, Hu, Yang, Zhu, Liu, Zhang, Wu and Jin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Deng</LastName><ForeName>Shasha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Zhihao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Structural Immunology, the Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yunru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Structural Immunology, the Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Structural Immunology, the Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Structural Immunology, the Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hongliang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Songquan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Tengchuan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Structural Immunology, the Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences and Health Laboratory of Anhui Province, University of Science &amp; Technology of China, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011948" MajorTopicYN="Y">Receptors, Antigen, T-Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="Y">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TCR repertoire</Keyword><Keyword MajorTopicYN="N">TCR-pHLA</Keyword><Keyword MajorTopicYN="N">TCR-pMHC</Keyword><Keyword MajorTopicYN="N">cytotoxic T lymphocytes (CTL)</Keyword><Keyword MajorTopicYN="N">epitope</Keyword><Keyword MajorTopicYN="N">mutations</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39450171</ArticleId><ArticleId IdType="pmc">PMC11499136</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1468456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMoa2001017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. (2020) 323:1239–42. doi: 10.1001/jama.2020.2648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. . Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama. (2020) 323:1574–81. doi: 10.1001/jama.2020.5394</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5394</ArticleId><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. . Antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity. Cell. (2020) 183:996–1012.e19. doi: 10.1016/j.cell.2020.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Adaptive immunity to SARS-coV-2 and COVID-19. Cell. (2021) 184:861–80. doi: 10.1016/j.cell.2021.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. (2020) 584:437–42. doi: 10.1038/s41586-020-2456-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL, Pekosz A, Park H-S, Ursin RL, Shapiro JR, Benner SE, et al. . Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. (2020) 130:6141–50. doi: 10.1172/JCI142004</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI142004</ArticleId><ArticleId IdType="pmc">PMC7598041</ArticleId><ArticleId IdType="pubmed">32764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. (2020) 26:1200–4. doi: 10.1038/s41591-020-0965-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0965-6</ArticleId><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. . SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. (2020) 587:270–4. doi: 10.1038/s41586-020-2598-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2598-9</ArticleId><ArticleId IdType="pubmed">32726801</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. . Targets of T cell responses to SARS-coV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. (2020) 181:1489–1501 e15. doi: 10.1016/j.cell.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. (2020) 584:457–62. doi: 10.1038/s41586-020-2550-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. . Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. (2020) 21:1336–45. doi: 10.1038/s41590-020-0782-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. (2020) 183:158–168 e14. doi: 10.1016/j.cell.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang F, Quan Y, Xin Z-T, Wrammert J, Ma M-J, Lv H, et al. . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study. J Immunol. (2011) 186:7264–8. doi: 10.4049/jimmunol.0903490</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903490</ArticleId><ArticleId IdType="pubmed">21576510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng O-W, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, et al. . Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. (2016) 34:2008–14. doi: 10.1016/j.vaccine.2016.02.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.063</ArticleId><ArticleId IdType="pmc">PMC7115611</ArticleId><ArticleId IdType="pubmed">26954467</ArticleId></ArticleIdList></Reference><Reference><Citation>Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. . Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. (2020) 31:565–9. doi: 10.1111/pai.13263</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.13263</ArticleId><ArticleId IdType="pmc">PMC7264678</ArticleId><ArticleId IdType="pubmed">32319118</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. . Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. (2020) 26:453–5. doi: 10.1038/s41591-020-0819-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0819-2</ArticleId><ArticleId IdType="pmc">PMC7095036</ArticleId><ArticleId IdType="pubmed">32284614</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. . Viral and host factors related to the clinical outcome of COVID-19. Nature. (2020) 583:437–40. doi: 10.1038/s41586-020-2355-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2355-0</ArticleId><ArticleId IdType="pubmed">32434211</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina AA, Komech EA, Titov A, Bensouda Koraichi M, Rosati E, Mamedov IZ, et al. . Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. Elife. (2021) 10:e63502. doi: 10.7554/eLife.63502</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.63502</ArticleId><ArticleId IdType="pmc">PMC7806265</ArticleId><ArticleId IdType="pubmed">33399535</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M, Popa A, et al. . SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses. Sci Immunol. (2021) 6:eabg6461. doi: 10.1126/sciimmunol.abg6461</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg6461</ArticleId><ArticleId IdType="pmc">PMC8224398</ArticleId><ArticleId IdType="pubmed">33664060</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. (2021) 371:eabf4063. doi: 10.1126/science.abf4063</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. . Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. (2021) 22:620–6. doi: 10.1038/s41590-021-00902-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00902-8</ArticleId><ArticleId IdType="pmc">PMC7610739</ArticleId><ArticleId IdType="pubmed">33674800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. . BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. (2021) 595:572–7. doi: 10.1038/s41586-021-03653-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03653-6</ArticleId><ArticleId IdType="pubmed">34044428</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. . Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. (2020) 5:eabd2071. doi: 10.1126/sciimmunol.abd2071</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd2071</ArticleId><ArticleId IdType="pmc">PMC7319493</ArticleId><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SGE, Parham P, Barber LD. Evolution and anthropology of HLA. The HLA Facts Book. London: Academic Press; (2000), 73–83.</Citation></Reference><Reference><Citation>Falk K, Rötzschke O, Stevanović S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. J Immunol (Baltimore Md.: 1950). (2006) 177:2741–7. doi: 101038/351290a0</Citation><ArticleIdList><ArticleId IdType="pubmed">16920906</ArticleId></ArticleIdList></Reference><Reference><Citation>Rammensee H-G, Falk K, Rötzschke O. MHC molecules as peptide receptors. Curr Opin Immunol. (1993) 5:35–44. doi: 10.1016/0952-7915(93)90078-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0952-7915(93)90078-7</ArticleId><ArticleId IdType="pubmed">7680871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Kolesnikov A, Yin R, Guest JD, Gowthaman R, Shmelev A, et al. . Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors. Nat Commun. (2022) 13:19–9. doi: 10.1038/s41467-021-27669-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27669-8</ArticleId><ArticleId IdType="pmc">PMC8748687</ArticleId><ArticleId IdType="pubmed">35013235</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, et al. . Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell. (2022) 185:2936–2951 e19. doi: 10.1016/j.cell.2022.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.07.002</ArticleId><ArticleId IdType="pmc">PMC9279490</ArticleId><ArticleId IdType="pubmed">35931021</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Lineburg KE, Panikkar A, Raju J, Murdolo LD, Szeto C, et al. . Ablation of CD8(+) T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3. Nat Commun. (2022) 13:6387. doi: 10.1038/s41467-022-34180-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34180-1</ArticleId><ArticleId IdType="pmc">PMC9607807</ArticleId><ArticleId IdType="pubmed">36302758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kombe Kombe AJ, Biteghe FAN, Ndoutoume ZN, Jin T. CD8(+) T-cell immune escape by SARS-CoV-2 variants of concern. Front Immunol. (2022) 13:962079. doi: 10.3389/fimmu.2022.962079</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.962079</ArticleId><ArticleId IdType="pmc">PMC9647062</ArticleId><ArticleId IdType="pubmed">36389664</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiñones-Parra S, Grant E, Loh L, Nguyen TH, Campbell K-A, Tong SY, et al. . Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci. (2014) 111:1049–54. doi: 101016/s0140-6736(70)90244-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903243</ArticleId><ArticleId IdType="pubmed">24395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, et al. . HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. Proc Natl Acad Sci. (2013) 110:13492–7. doi: 10.1073/pnas.1221555110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1221555110</ArticleId><ArticleId IdType="pmc">PMC3746844</ArticleId><ArticleId IdType="pubmed">23878211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenney AD, Dowdle JA, Bozzacco L, McMichael TM, St Gelais C, Panfil AR, et al. . Human genetic determinants of viral diseases. Annu Rev Genet. (2017) 51:241–63. doi: 10.1146/annurev-genet-120116-023425</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genet-120116-023425</ArticleId><ArticleId IdType="pmc">PMC6038703</ArticleId><ArticleId IdType="pubmed">28853921</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter-Timofte ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen N-S, Al-Mousawi A, et al. . Deciphering the role of host genetics in susceptibility to severe COVID-19. Front Immunol. (2020) 11:1606. doi: 10.3389/fimmu.2020.01606</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01606</ArticleId><ArticleId IdType="pmc">PMC7338588</ArticleId><ArticleId IdType="pubmed">32695122</ArticleId></ArticleIdList></Reference><Reference><Citation>JL A. Study of leucocyte phenotypes in Hodgkins’ disease. Lancet. (1967) 2(7676):771–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">4195991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunardi LW. Bragatte, M.A.d.S. &amp; Vieira, G.F. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view. Braz J Infect Dis. (2021) 25:101619. doi: 10.1016/j.bjid.2021.101619</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2021.101619</ArticleId><ArticleId IdType="pmc">PMC9392165</ArticleId><ArticleId IdType="pubmed">34562387</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. . HLA and HIV-1: heterozygote advantage and B*35-cw*04 disadvantage. Science. (1999) 283:1748–52. doi: 10.1126/science.283.5408.1748</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.283.5408.1748</ArticleId><ArticleId IdType="pubmed">10073943</ArticleId></ArticleIdList></Reference><Reference><Citation>Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, et al. . Influence of HLA-C expression level on HIV control. Science. (2013) 340:87–91. doi: 10.1126/science.1232685</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232685</ArticleId><ArticleId IdType="pmc">PMC3784322</ArticleId><ArticleId IdType="pubmed">23559252</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwell Jenefer M, Jamieson Sarra E, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. (2009) 22:370–85. doi: 10.1128/CMR.00048-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00048-08</ArticleId><ArticleId IdType="pmc">PMC2668228</ArticleId><ArticleId IdType="pubmed">19366919</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. . Mapping the human genetic architecture of COVID-19. Nature. (2021) 600:472–7. doi: 10.1038/s41586-021-03767-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03767-x</ArticleId><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Shachar S, Barda N, Manor S, Israeli S, Dagan N, Carmi S, et al. . MHC haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of COVID-19 in the Israeli population. J Clin Immunol. (2021) 41:1154–61. doi: 10.1007/s10875-021-01071-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01071-x</ArticleId><ArticleId IdType="pmc">PMC8164405</ArticleId><ArticleId IdType="pubmed">34050837</ArticleId></ArticleIdList></Reference><Reference><Citation>Shkurnikov M, Nersisyan S, Jankevic T, Galatenko A, Gordeev I, Vechorko V, et al. . Association of HLA class I genotypes with severity of coronavirus disease-19. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.641900</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.641900</ArticleId><ArticleId IdType="pmc">PMC7959787</ArticleId><ArticleId IdType="pubmed">33732261</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzurez A, Naka I, Miki S, Nakayama-Hosoya K, Isshiki M, Watanabe Y, et al. . Association of HLA-*09:01 with severe COVID-19. HLA. (2021) 98:37–42. doi: 10.1111/tan.14256</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14256</ArticleId><ArticleId IdType="pmc">PMC8251239</ArticleId><ArticleId IdType="pubmed">33734601</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung Y-L, Cheng C-K, Chan H-Y, Xia JT, Lau K-M, Wong RSM, et al. . Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients. HLA. (2021) 97:127–32. doi: 10.1111/tan.14135</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14135</ArticleId><ArticleId IdType="pmc">PMC7898481</ArticleId><ArticleId IdType="pubmed">33179437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19). Hla. (2020) 96:194–6. doi: 10.1111/tan.13941</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.13941</ArticleId><ArticleId IdType="pmc">PMC7276866</ArticleId><ArticleId IdType="pubmed">32424945</ArticleId></ArticleIdList></Reference><Reference><Citation>Null N. Genomewide association study of severe covid-19 with respiratory failure. New Engl J Med. (2020) 383:1522–34. doi: 10.1056/NEJMoa2020283</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2020283</ArticleId><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, et al. . HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. Hla. (2020) 96:610–4. doi: 10.1111/tan.14047</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14047</ArticleId><ArticleId IdType="pmc">PMC7461491</ArticleId><ArticleId IdType="pubmed">32827207</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoroso A, Magistroni P, Vespasiano F, Bella A, Bellino S, Puoti F, et al. . HLA and AB0 polymorphisms may influence SARS-coV-2 infection and COVID-19 severity. Transplantation. (2021) 105:193–200. doi: 10.1097/TP.0000000000003507</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003507</ArticleId><ArticleId IdType="pubmed">33141807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente L, Martín MM, Franco A, Barrios Y, Cáceres JJ, Solé-Violán J, et al. . HLA genetic polymorphisms and prognosis of patients with COVID-19. Med Intensiva. (2021) 45:96–103. doi: 10.1016/j.medin.2020.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7474921</ArticleId><ArticleId IdType="pubmed">38620408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, et al. . Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discovery. (2020) 6:83. doi: 10.1038/s41421-020-00231-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00231-4</ArticleId><ArticleId IdType="pmc">PMC7653987</ArticleId><ArticleId IdType="pubmed">33298875</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite M, Gonzalez-Galarza FF, Silva B, Middleton D, Santos E. Predictive immunogenetic markers in COVID-19. Hum Immunol. (2021) 82:247–54. doi: 10.1016/j.humimm.2021.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2021.01.008</ArticleId><ArticleId IdType="pmc">PMC7817393</ArticleId><ArticleId IdType="pubmed">33546902</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisanti S, Deelen J, Gallina AM, Caputo M, Citro M, Abate M, et al. . Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Trans Med. (2020) 18:1–16. doi: 10.1186/s12967-020-02515-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02515-5</ArticleId><ArticleId IdType="pmc">PMC7491019</ArticleId><ArticleId IdType="pubmed">32933522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacher P, Rosati E, Esser D, Martini GR, Saggau C, Schiminsky E, et al. . Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity. (2020) 53:1258–1271. e5. doi: 10.1016/j.immuni.2020.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.016</ArticleId><ArticleId IdType="pmc">PMC7689350</ArticleId><ArticleId IdType="pubmed">33296686</ArticleId></ArticleIdList></Reference><Reference><Citation>Khor S-S, Omae Y, Nishida N, Sugiyama M, Kinoshita N, Suzuki T, et al. . HLA-A* 11: 01: 01: 01, HLA-C* 12: 02: 02: 01-HLA-B* 52: 01: 02: 02, age and sex are associated with severity of Japanese COVID-19 with respiratory failure. Front Immunol. (2021) 12:658570. doi: 10.3389/fimmu.2021.658570</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658570</ArticleId><ArticleId IdType="pmc">PMC8100314</ArticleId><ArticleId IdType="pubmed">33968060</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Mueller M, et al. . Increased risk of severe clinical course of COVID-19 in carriers of HLA-C* 04: 01. EClinicalMedicine. (2021) 40:101099. doi: 10.1016/j.eclinm.2021.101099</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101099</ArticleId><ArticleId IdType="pmc">PMC8410317</ArticleId><ArticleId IdType="pubmed">34490415</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietzen H, Zoufaly A, Traugott M, Aberle J, Aberle SW, Puchhammer-Stöckl E. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. Genet Med. (2021) 23:963–7. doi: 10.1038/s41436-020-01077-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-020-01077-7</ArticleId><ArticleId IdType="pmc">PMC7835668</ArticleId><ArticleId IdType="pubmed">33500568</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler E, Dribus M, Duffy BF, Hock K, Farnsworth CW, Gragert L, et al. . HLA genetic polymorphism in patients with Coronavirus Disease 2019 in Midwestern United States. Hla. (2021) 98:370–9. doi: 10.1111/tan.14387</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14387</ArticleId><ArticleId IdType="pmc">PMC8429120</ArticleId><ArticleId IdType="pubmed">34338446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, et al. . Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. (2020) 94:e00510-20. doi: 10.1128/jvi.00510-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00510-20</ArticleId><ArticleId IdType="pmc">PMC7307149</ArticleId><ArticleId IdType="pubmed">32303592</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto DG, Murdolo LD, Chatzileontiadou DSM, Sabatino JJ, Yusufali T, Peyser ND, et al. et al. . A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. (2023) 620:128–36. doi: 10.1038/s41586-023-06331-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06331-x</ArticleId><ArticleId IdType="pmc">PMC10396966</ArticleId><ArticleId IdType="pubmed">37468623</ArticleId></ArticleIdList></Reference><Reference><Citation>Triunfol M. HLA-B*15:01 allele and asymptomatic SARS-CoV-2 infection. Lancet Respir Med. (2023) 11:e83. doi: 10.1016/S2213-2600(23)00295-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00295-3</ArticleId><ArticleId IdType="pubmed">37549678</ArticleId></ArticleIdList></Reference><Reference><Citation>Littera R, Campagna M, Deidda S, Angioni G, Cipri S, Melis M, et al. . Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. The Sardinian experience. Front Immunol. (2020) 11:605688. doi: 10.3389/fimmu.2020.605688</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.605688</ArticleId><ArticleId IdType="pmc">PMC7746644</ArticleId><ArticleId IdType="pubmed">33343579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M, Tseng H-K, Trejaut JA, Lee H-L, Loo J-H, Chu C-C, et al. . Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. (2003) 4:9–9. doi: 10.1186/1471-2350-4-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2350-4-9</ArticleId><ArticleId IdType="pmc">PMC212558</ArticleId><ArticleId IdType="pubmed">12969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Sidney J, Vita R, Peters B, Crotty S, Weiskopf D, et al. . SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell Host Microbe. (2021) 29:1076–92. doi: 10.1016/j.chom.2021.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8139264</ArticleId><ArticleId IdType="pubmed">34237248</ArticleId></ArticleIdList></Reference><Reference><Citation>
Immune Epitope Database (IEDB) . (2023). Available online at: http://www.iedb.org/. (accessed April 25, 2024).</Citation></Reference><Reference><Citation>Ferretti AP, Kula T, Wang Y, Nguyen DMV, Weinheimer A, Dunlap GS, et al. . Unbiased screens show CD8(+) T cells of COVID-19 patients recognize shared epitopes in SARS-coV-2 that largely reside outside the spike protein. Immunity. (2020) 53:1095–1107 e3. doi: 10.1016/j.immuni.2020.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.10.006</ArticleId><ArticleId IdType="pmc">PMC7574860</ArticleId><ArticleId IdType="pubmed">33128877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. . SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. (2021) 22:74–85. doi: 10.1038/s41590-020-00808-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00808-x</ArticleId><ArticleId IdType="pubmed">32999467</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, et al. . Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. (2021) 2:100204. doi: 10.1016/j.xcrm.2021.100204</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100204</ArticleId><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, et al. . SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood J Am Soc Hematol. (2020) 136:2905–17. doi: 10.1182/blood.2020008488</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008488</ArticleId><ArticleId IdType="pmc">PMC7746091</ArticleId><ArticleId IdType="pubmed">33331927</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen SS, Vibholm LK, Monrad I, Olesen R, Frattari GS, Pahus MH, et al. . SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine. (2021) 68:103410. doi: 10.1016/j.ebiom.2021.103410</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103410</ArticleId><ArticleId IdType="pmc">PMC8176920</ArticleId><ArticleId IdType="pubmed">34098342</ArticleId></ArticleIdList></Reference><Reference><Citation>Shomuradova AS, Vagida MS, Sheetikov SA, Zornikova KV, Kiryukhin D, Titov A, et al. . SARS-coV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors. Immunity. (2020) 53:1245–1257.e5. doi: 10.1016/j.immuni.2020.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7664363</ArticleId><ArticleId IdType="pubmed">33326767</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, et al. . Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. (2021) 596:268–72. doi: 10.1038/s41586-021-03681-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03681-2</ArticleId><ArticleId IdType="pmc">PMC8357629</ArticleId><ArticleId IdType="pubmed">34107529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. . PD-1-expressing SARS-coV-2-specific CD8(+) T cells are not exhausted, but functional in patients with COVID-19. Immunity. (2021) 54:44–52 e3. doi: 10.1016/j.immuni.2020.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7834198</ArticleId><ArticleId IdType="pubmed">33338412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. . BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. MedRxiv. (2020) 2020:12. 09.20245175. doi: 101038/s41586-021-03653-6</Citation></Reference><Reference><Citation>Saini SK, Hersby DS, Tamhane T, Povlsen HR, Hernandez SPA, Nielsen M, et al. . SARS-CoV-2 genome-wide mapping of CD8 T cell recognition reveals strong immunodominance and substantial CD8 T cell activation in COVID-19 patients. Sci Immunol. (2020) 6(58):eabf7550. doi: 10.1101/2020.10.19.344911</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.19.344911</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini SK, Hersby DS, Tamhane T, Povlsen HR, Hernandez SPA, Nielsen M, et al. . SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8(+) T cell activation in COVID-19 patients. Sci Immunol. (2021) 6:eabf7550. doi: 10.1126/sciimmunol.abf7550</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf7550</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, et al. . Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature. (2021) 597:268–73. doi: 10.1038/s41586-021-03841-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03841-4</ArticleId><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, et al. . Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological Malignancy impacting B cells. Cell Rep Med. (2023) 4:101017. doi: 10.1016/j.xcrm.2023.101017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101017</ArticleId><ArticleId IdType="pmc">PMC10040362</ArticleId><ArticleId IdType="pubmed">37030296</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina AA, Pogorelyy MV, Kirk AM, Allen EK, Allison KJ, Lin C-Y, et al. . Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination. Nat Immunol. (2021) 23(5):781–90. doi: 101038/s41590-022-01184-4</Citation></Reference><Reference><Citation>Nguyen THO, Rowntree LC, Petersen J, Chua BY, Hensen L, Kedzierski L, et al. . CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity. (2021) 54:1066–1082 e5. doi: 10.1016/j.immuni.2021.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.04.009</ArticleId><ArticleId IdType="pmc">PMC8049468</ArticleId><ArticleId IdType="pubmed">33951417</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto C, Nguyen AT, Lobos CA, Chatzileontiadou DSM, Jayasinghe D, Grant EJ, et al. . Molecular basis of a dominant SARS-coV-2 spike-derived epitope presented by HLA-A*02:01 recognised by a public TCR. Cells. (2021) 10:2646. doi: 10.3390/cells10102646</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102646</ArticleId><ArticleId IdType="pmc">PMC8534114</ArticleId><ArticleId IdType="pubmed">34685626</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowntree LC, Nguyen THO, Kedzierski L, Neeland MR, Petersen J, Crawford JC, et al. . SARS-CoV-2-specific T cell memory with common TCRalphabeta motifs is established in unvaccinated children who seroconvert after infection. Immunity. (2022) 55:1299–1315 e4. doi: 10.1016/j.immuni.2022.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.06.003</ArticleId><ArticleId IdType="pmc">PMC9174177</ArticleId><ArticleId IdType="pubmed">35750048</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowntree LC, Petersen J, Juno JA, Chaurasia P, Wragg K, Koutsakos M, et al. . SARS-CoV-2-specific CD8(+) T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. Immunol Cell Biol. (2021) 99:990–1000. doi: 10.1111/imcb.12482</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12482</ArticleId><ArticleId IdType="pmc">PMC8242669</ArticleId><ArticleId IdType="pubmed">34086357</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis JA-O, Leistritz-Edwards DA-O, Dunn AA-O, Tarr C, Lehman JA-O, Dempsey C, et al. . Allelic variation in class I HLA determines CD8(+) T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Sci Immunol. (2021) 7(67):eabk3070. doi: 101126/sciimmunolabk3070</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017864</ArticleId><ArticleId IdType="pubmed">34793243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lineburg KE, Grant EJ, Swaminathan S, Chatzileontiadou DS, Szeto C, Sloane H, et al. . CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity. (2021) 54:1055–1065. e5. doi: 10.1016/j.immuni.2021.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.04.006</ArticleId><ArticleId IdType="pmc">PMC8043652</ArticleId><ArticleId IdType="pubmed">33945786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C, Shen M, Han X, Chen Q, Li L, Chen S, et al. . Identification of cross-reactive CD8(+) T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants. Genes Dis. (2022) 9:216–29. doi: 10.1016/j.gendis.2021.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC8240504</ArticleId><ArticleId IdType="pubmed">34222571</ArticleId></ArticleIdList></Reference><Reference><Citation>Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol. (2012) 12:295–305. doi: 10.1038/nri3166</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3166</ArticleId><ArticleId IdType="pmc">PMC3364025</ArticleId><ArticleId IdType="pubmed">22402670</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, Hsu NS, et al. . The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience. (2021) 24:103353. doi: 10.1016/j.isci.2021.103353</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103353</ArticleId><ArticleId IdType="pmc">PMC8552693</ArticleId><ArticleId IdType="pubmed">34729465</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Xiao C, Wang Z, Zhu G, Mao L, Chen X, et al. . CD8(+) T-cell epitope variations suggest a potential antigen HLA-A2 binding deficiency for spike protein of SARS-coV-2. Front Immunol. (2021) 12:764949. doi: 103389/fimmu2021764949</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8804355</ArticleId><ArticleId IdType="pubmed">35116022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al. . Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol. (2022) 8:veac050–veac050. doi: 10.1093/ve/veac050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veac050</ArticleId><ArticleId IdType="pmc">PMC9384748</ArticleId><ArticleId IdType="pubmed">35996593</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, et al. . SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. (2021) 29:1124–1136 e11. doi: 10.1016/j.chom.2021.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.006</ArticleId><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. . Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Rep. (2021) 36:109708. doi: 10.1016/j.celrep.2021.109708</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109708</ArticleId><ArticleId IdType="pmc">PMC8390359</ArticleId><ArticleId IdType="pubmed">34506741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol. (2009) 9:503–13. doi: 10.1038/nri2575</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2575</ArticleId><ArticleId IdType="pubmed">19498380</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley MF, Greenaway HY, Venturi V, Lindsay R, Quinn KM, Seder RA, et al. . Convergent recombination shapes the clonotypic landscape of the naive T-cell repertoire. Proc Natl Acad Sci. (2010) 107:19414–9. doi: 10.1073/pnas.1010586107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010586107</ArticleId><ArticleId IdType="pmc">PMC2984183</ArticleId><ArticleId IdType="pubmed">20974936</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Sikora MJ, Islam S, Chowdhury RR, Chien Y-h, Scriba TJ, et al. . Select sequencing of clonally expanded CD8+ T cells reveals limits to clonal expansion. Proc Natl Acad Sci. (2019) 116:8995–9001. doi: 10.1073/pnas.1902649116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1902649116</ArticleId><ArticleId IdType="pmc">PMC6500157</ArticleId><ArticleId IdType="pubmed">30992377</ArticleId></ArticleIdList></Reference><Reference><Citation>Britanova OV, Shugay M, Merzlyak EM, Staroverov DB, Putintseva EV, Turchaninova MA, et al. . Dynamics of individual T cell repertoires: from cord blood to centenarians. J Immunol. (2016) 196:5005–13. doi: 10.4049/jimmunol.1600005</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600005</ArticleId><ArticleId IdType="pubmed">27183615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez L, Beckford J, Alachkar H. Deciphering the TCR repertoire to solve the COVID-19 mystery. Trends Pharmacol Sci. (2020) 41:518–30. doi: 10.1016/j.tips.2020.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7305739</ArticleId><ArticleId IdType="pubmed">32576386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Sant S, Bird NL, Grant EJ, Clemens EB, Koutsakos M, et al. . Perturbed CD8+ T cell immunity across universal influenza epitopes in the elderly. J Leukocyte Biol. (2018) 103:321–39. doi: 10.1189/jlb.5MA0517-207R</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.5MA0517-207R</ArticleId><ArticleId IdType="pubmed">28928269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil A, Yassai MB, Naumov YN, Selin LK. Narrowing of human influenza A virus-specific T cell receptor α and β repertoires with increasing age. J Virol. (2015) 89:4102–16. doi: 10.1128/JVI.03020-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03020-14</ArticleId><ArticleId IdType="pmc">PMC4442365</ArticleId><ArticleId IdType="pubmed">25609818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 46:846–8. doi: 10.1007/s00134-020-05991-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon E, Sibener LV, Battle A, Fraser HB, Garcia KC, Pritchard JK, et al. . Genetic variation in MHC proteins is associated with T cell receptor expression biases. Nat Genet. (2016) 48:995–1002. doi: 10.1038/ng.3625</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3625</ArticleId><ArticleId IdType="pmc">PMC5010864</ArticleId><ArticleId IdType="pubmed">27479906</ArticleId></ArticleIdList></Reference><Reference><Citation>Falfán-Valencia R, Narayanankutty A, Reséndiz-Hernández JM, Pérez-Rubio G, Ramírez-Venegas A, Nava-Quiroz KJ, et al. . An increased frequency in HLA class I alleles and haplotypes suggests genetic susceptibility to influenza A (H1N1) 2009 pandemic: A case-control study. J Immunol Res. (2018) 2018:3174868. doi: 10.1155/2018/3174868</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3174868</ArticleId><ArticleId IdType="pmc">PMC5845504</ArticleId><ArticleId IdType="pubmed">29682588</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas MS, Rachel MG, Mark K, Damon HM, Edward JO, Ruth T, et al. . Magnitude and dynamics of the T-cell response to SARS-coV-2 infection at both individual and population levels. medRxiv. (2020) 17:2020073120165647. doi: 101101/2020073120165647</Citation></Reference><Reference><Citation>Adamo S, Michler J, Zurbuchen Y, Cervia C, Taeschler P, Raeber ME, et al. . Signature of long-lived memory CD8(+) T cells in acute SARS-CoV-2 infection. Nature. (2022) 602:148–55. doi: 10.1038/s41586-021-04280-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04280-x</ArticleId><ArticleId IdType="pmc">PMC8810382</ArticleId><ArticleId IdType="pubmed">34875673</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Liang W, Pang J, Xu G, Chen Y, Guo X, et al. . Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. Cell Discovery. (2021) 7:89. doi: 10.1038/s41421-021-00321-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00321-x</ArticleId><ArticleId IdType="pmc">PMC8476510</ArticleId><ArticleId IdType="pubmed">34580278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. . T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci Trans Med. (2021) 13:eabf7517. doi: 10.1126/scitranslmed.abf7517</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf7517</ArticleId><ArticleId IdType="pmc">PMC8128286</ArticleId><ArticleId IdType="pubmed">33723016</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. . Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med. (2021) 2:100354. doi: 10.1016/j.xcrm.2021.100354</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100354</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zornikova KV, Khmelevskaya A, Sheetikov SA, Kiryukhin DO, Shcherbakova OV, Titov A, et al. . Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response. Commun Biol. (2022) 5:1351. doi: 10.1038/s42003-022-04250-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-04250-7</ArticleId><ArticleId IdType="pmc">PMC9734123</ArticleId><ArticleId IdType="pubmed">36494499</ArticleId></ArticleIdList></Reference><Reference><Citation>Miconnet I, Marrau A, Farina A, Taffé P, Vigano S, Harari  , et al. . Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure. J Immunol. (2011) 186:7039–49. doi: 10.4049/jimmunol.1003309</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1003309</ArticleId><ArticleId IdType="pubmed">21555537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette A, et al. . Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature. (2017) 547:89–93. doi: 10.1038/nature22383</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22383</ArticleId><ArticleId IdType="pmc">PMC5616171</ArticleId><ArticleId IdType="pubmed">28636592</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, Roederer M, et al. . Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med. (2005) 202:1349–61. doi: 10.1084/jem.20051357</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20051357</ArticleId><ArticleId IdType="pmc">PMC2212993</ArticleId><ArticleId IdType="pubmed">16287711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature. (2009) 458:211–4. doi: 10.1038/nature07657</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07657</ArticleId><ArticleId IdType="pmc">PMC2735344</ArticleId><ArticleId IdType="pubmed">19182777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sureshchandra S, Lewis SA, Doratt BM, Jankeel A, Ibraim IC, Messaoudi I. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. JCI Insight. (2021) 6:e153201. doi: 10.1172/jci.insight.153201</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.153201</ArticleId><ArticleId IdType="pmc">PMC8783687</ArticleId><ArticleId IdType="pubmed">34935643</ArticleId></ArticleIdList></Reference><Reference><Citation>Taus E, Hofmann C, Ibarrondo FJ, Gong LS, Hausner MA, Fulcher JA, et al. . Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. Front Immunol. (2023) 14. doi: 10.3389/fimmu.2023.1100594</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1100594</ArticleId><ArticleId IdType="pmc">PMC9968837</ArticleId><ArticleId IdType="pubmed">36860850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Mayer-Blackwell K, Jing L, Laing KJ, Sholukh AM, St Germain R, et al. . Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19. Nat Immunol. (2024) 25:166–77. doi: 10.1038/s41590-023-01692-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01692-x</ArticleId><ArticleId IdType="pmc">PMC10981451</ArticleId><ArticleId IdType="pubmed">38057617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Blackwell K, Ryu H, Codd AS, Parks KR, MacMillan HR, Cohen KW, et al. . mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RAint TEMRA-like CD8+ T cells in COVID-19 recovered individuals. Cell Rep Med. (2023) 4:101149. doi: 10.1016/j.xcrm.2023.101149</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101149</ArticleId><ArticleId IdType="pmc">PMC10439252</ArticleId><ArticleId IdType="pubmed">37552991</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki H, Kitabatake M, Abe H, Xu P, Tsunoda M, Shichino S, et al. . CD8+ T cell memory induced by successive SARS-CoV-2 mRNA vaccinations is characterized by shifts in clonal dominance. Cell Rep. (2024) 43:113887. doi: 10.1016/j.celrep.2024.113887</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2024.113887</ArticleId><ArticleId IdType="pubmed">38458195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang-Meli J, Luxenburger H, Wild K, Karl V, Oberhardt V, Salimi Alizei E, et al. . SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals. Nat Microbiol. (2022) 7:675–9. doi: 10.1038/s41564-022-01106-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01106-y</ArticleId><ArticleId IdType="pmc">PMC9064790</ArticleId><ArticleId IdType="pubmed">35484232</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, et al. . Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature. (1994) 370:463–7. doi: 10.1038/370463a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/370463a0</ArticleId><ArticleId IdType="pubmed">8047166</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Jin X, Zhou W, Luo M, Xu Z, Xu C, et al. . Comprehensive analysis of TCR repertoire in COVID-19 using single cell sequencing. Genomics. (2021) 113:456–62. doi: 10.1016/j.ygeno.2020.12.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2020.12.036</ArticleId><ArticleId IdType="pmc">PMC7833309</ArticleId><ArticleId IdType="pubmed">33383142</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai H, Ma J, Mao W, Zhang X, Nie Y, Hao J, et al. . Identification of TCR repertoires in asymptomatic COVID-19 patients by single-cell T-cell receptor sequencing. Blood Cells Molecules Dis. (2022) 97:102678. doi: 10.1016/j.bcmd.2022.102678</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcmd.2022.102678</ArticleId><ArticleId IdType="pmc">PMC9162783</ArticleId><ArticleId IdType="pubmed">35716403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen K, Datta S, Ghosh A, Jha A, Ahad A, Chatterjee S, et al. . Single-cell immunogenomic approach identified SARS-CoV-2 protective immune signatures in asymptomatic direct contacts of COVID-19 cases. Front Immunol. (2021) 12:733539. doi: 10.3389/fimmu.2021.733539</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.733539</ArticleId><ArticleId IdType="pmc">PMC8660575</ArticleId><ArticleId IdType="pubmed">34899693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MH, Zhang S, Porritt RA, Noval Rivas M, Paschold L, Willscher E, et al. . Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci. (2020) 117:25254–62. doi: 10.1073/pnas.2010722117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010722117</ArticleId><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhom J-W, Baras AS. Deep learning identifies antigenic determinants of severe SARS-CoV-2 infection within T-cell repertoires. Sci Rep. (2021) 11:14275. doi: 10.1038/s41598-021-93608-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-93608-8</ArticleId><ArticleId IdType="pmc">PMC8275616</ArticleId><ArticleId IdType="pubmed">34253751</ArticleId></ArticleIdList></Reference><Reference><Citation>Laydon DJ, Bangham CRM, Asquith B. Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach. Philos Trans R Soc B: Biol Sci. (2015) 370:20140291. doi: 10.1098/rstb.2014.0291</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2014.0291</ArticleId><ArticleId IdType="pmc">PMC4528489</ArticleId><ArticleId IdType="pubmed">26150657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolich-Žugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol. (2004) 4:123–32. doi: 10.1038/nri1292</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1292</ArticleId><ArticleId IdType="pubmed">15040585</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, et al. . Identifying specificity groups in the T cell receptor repertoire. Nature. (2017) 547:94–8. doi: 10.1038/nature22976</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22976</ArticleId><ArticleId IdType="pmc">PMC5794212</ArticleId><ArticleId IdType="pubmed">28636589</ArticleId></ArticleIdList></Reference><Reference><Citation>Venturi V, Price DA, Douek DC, Davenport MP. The molecular basis for public T-cell responses? Nat Rev Immunol. (2008) 8:231–8. doi: 101038/nri2260</Citation><ArticleIdList><ArticleId IdType="pubmed">18301425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, et al. . TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol. (2012) 13:691–700. doi: 10.1038/ni.2342</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2342</ArticleId><ArticleId IdType="pmc">PMC3538851</ArticleId><ArticleId IdType="pubmed">22683743</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, et al. . Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood. (2009) 113:6351–60. doi: 10.1182/blood-2009-02-206557</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-02-206557</ArticleId><ArticleId IdType="pmc">PMC2710928</ArticleId><ArticleId IdType="pubmed">19389882</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee J-Y, et al. . Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci. (2014) 111:13139–44. doi: 10.1073/pnas.1409155111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1409155111</ArticleId><ArticleId IdType="pmc">PMC4246948</ArticleId><ArticleId IdType="pubmed">25157137</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulien I, Kemming J, Oberhardt V, Wild K, Seidel LM, Killmer S, et al. . Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat Med. (2021) 27:78–85. doi: 10.1038/s41591-020-01143-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01143-2</ArticleId><ArticleId IdType="pubmed">33184509</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina AA, Pogorelyy MV, Kirk AM, Crawford JC, Allen EK, Chou C-H, et al. . SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat Immunol. (2022) 23:781–90. doi: 10.1038/s41590-022-01184-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01184-4</ArticleId><ArticleId IdType="pmc">PMC9106845</ArticleId><ArticleId IdType="pubmed">35383307</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncharov M, Bagaev D, Shcherbinin D, Zvyagin I, Bolotin D, Thomas PG, et al. . VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2. Nat Methods. (2022) 19:1017–9. doi: 10.1038/s41592-022-01578-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-022-01578-0</ArticleId><ArticleId IdType="pubmed">35970936</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogorelyy MV, Fedorova AD, McLaren JE, Ladell K, Bagaev DV, Eliseev AV, et al. . Exploring the pre-immune landscape of antigen-specific T cells. Genome Med. (2018) 10:68. doi: 10.1186/s13073-018-0577-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-018-0577-7</ArticleId><ArticleId IdType="pmc">PMC6109350</ArticleId><ArticleId IdType="pubmed">30144804</ArticleId></ArticleIdList></Reference><Reference><Citation>Culshaw A, Ladell K, Gras S, McLaren JE, Miners KL, Farenc C, et al. . Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response. Nat Immunol. (2017) 18:1228–37. doi: 10.1038/ni.3850</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3850</ArticleId><ArticleId IdType="pubmed">28945243</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DA, West SM, Betts MR, Ruff LE, Brenchley JM, Ambrozak DR, et al. . T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity. (2004) 21:793–803. doi: 10.1016/j.immuni.2004.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2004.10.010</ArticleId><ArticleId IdType="pubmed">15589168</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. . Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. (2020) 370:89–94. doi: 10.1126/science.abd3871</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3871</ArticleId><ArticleId IdType="pmc">PMC7574914</ArticleId><ArticleId IdType="pubmed">32753554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol. (2020) 20:457–8. doi: 10.1038/s41577-020-0389-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0389-z</ArticleId><ArticleId IdType="pmc">PMC7339790</ArticleId><ArticleId IdType="pubmed">32636479</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Iyoda T, Sanpei A, Nakazato H, Okada M, Ueda S, et al. . Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2. Commun Biol. (2021) 4:1365. doi: 10.1038/s42003-021-02885-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02885-6</ArticleId><ArticleId IdType="pmc">PMC8640030</ArticleId><ArticleId IdType="pubmed">34857854</ArticleId></ArticleIdList></Reference><Reference><Citation>Olafsdottir TA, Bjarnadottir K, Norddahl GL, Halldorsson GH, Melsted P, Gunnarsdottir K, et al. . HLA alleles, disease severity, and age associate with T-cell responses following infection with SARS-CoV-2. Commun Biol. (2022) 5:914. doi: 10.1038/s42003-022-03893-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03893-w</ArticleId><ArticleId IdType="pmc">PMC9446630</ArticleId><ArticleId IdType="pubmed">36068292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, et al. . SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J Clin Invest. (2021) 131:e145476. doi: 10.1172/JCI145476</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI145476</ArticleId><ArticleId IdType="pmc">PMC7919723</ArticleId><ArticleId IdType="pubmed">33427749</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley PR, Lee CH, Pereira Pinho M, Ottakandathil Babu R, Woo J, Antanaviciute A, et al. . HLA-dependent variation in SARS-CoV-2 CD8+ T cell cross-reactivity with human coronaviruses. Immunology. (2022) 166:78–103. doi: 10.1111/imm.v166.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.v166.1</ArticleId><ArticleId IdType="pmc">PMC9111820</ArticleId><ArticleId IdType="pubmed">35143694</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Dong D, Penkava F, Mentzer AJ, Yao X, et al. . An immunodominant NP105–113-B* 07: 02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat Immunol. (2022) 23:50–61. doi: 10.1038/s41590-021-01084-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01084-z</ArticleId><ArticleId IdType="pmc">PMC8709787</ArticleId><ArticleId IdType="pubmed">34853448</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanevich OV, Alekseeva EI, Sergeeva M, Fadeev AV, Komissarova KS, Ivanova AA, et al. . SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19. Nat Commun. (2023) 14:149. doi: 10.1038/s41467-022-34033-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34033-x</ArticleId><ArticleId IdType="pmc">PMC9831376</ArticleId><ArticleId IdType="pubmed">36627290</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. (2021) 2:100255–5. doi: 10.1016/j.xcrm.2021.100255</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100255</ArticleId><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington D, Yin Z, Yu Z, Heilig R, Davis S, Fischer R, et al. . SARS-CoV-2 mutations affect antigen processing by the proteasome to alter CD8+ T cell responses. Heliyon. (2023) 9:e20076. doi: 10.1016/j.heliyon.2023.e20076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e20076</ArticleId><ArticleId IdType="pmc">PMC10570596</ArticleId><ArticleId IdType="pubmed">37842619</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S, Xu Z, Wang M, Hu J, Liu Z, Zhu F, et al. . Structural insights into immune escape at killer T cell epitope by SARS-CoV-2 Spike Y453F variants. J Biol Chem. (2024) 300:107563. doi: 10.1016/j.jbc.2024.107563</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2024.107563</ArticleId><ArticleId IdType="pmc">PMC11342781</ArticleId><ArticleId IdType="pubmed">39002680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaurasia P, Nguyen THO, Rowntree LC, Juno JA, Wheatley AK, Kent SJ, et al. . Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. J Biol Chem. (2021) 297:101065. doi: 10.1016/j.jbc.2021.101065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.101065</ArticleId><ArticleId IdType="pmc">PMC8352664</ArticleId><ArticleId IdType="pubmed">34384783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Efimov GA, Bogolyubova AV, Pierce BG, Mariuzza RA. Structural insights into protection against a SARS-CoV-2 spike variant by T cell receptor diversity. J Biol Chem. (2023) 299:103035. doi: 10.1016/j.jbc.2023.103035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.103035</ArticleId><ArticleId IdType="pmc">PMC9934920</ArticleId><ArticleId IdType="pubmed">36806685</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Val M, Schlicht H-J, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell. (1991) 66:1145–53. doi: 10.1016/0092-8674(91)90037-Y</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90037-Y</ArticleId><ArticleId IdType="pubmed">1913805</ArticleId></ArticleIdList></Reference><Reference><Citation>Draenert R, Gall S, Pfafferott K, Leslie A, Chetty P, Brander C, et al. . Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med. (2004) 199:905–15. doi: 10.1084/jem.20031982</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20031982</ArticleId><ArticleId IdType="pmc">PMC2211885</ArticleId><ArticleId IdType="pubmed">15067030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe SRF, Kramer HB, Wright C, Kessler BM, di Gleria K, Zhang Y, et al. . The antiviral efficacy of HIV-specific CD8+ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PloS Pathog. (2011) 7:e1001341. doi: 10.1371/journal.ppat.1001341</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001341</ArticleId><ArticleId IdType="pmc">PMC3093356</ArticleId><ArticleId IdType="pubmed">21589893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>